Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Nov;15(6):709-10.
doi: 10.1038/aja.2013.96. Epub 2013 Jul 29.

Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation

Yuri Stanevsky  1 , Alexander Tsivian, Matvey Tsivian
Affiliations
Comment

Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation

Yuri Stanevsky et al. Asian J Androl. 2013 Nov.

Abstract

A new research study evaluated the mechanisms of prostate cancer (PCa) resistance to androgen deprivation therapy (ADT) and progression to castrate-resistant disease. Using a coclinical approach, the investigators were able to identify key genetic determinants of ADT resistance, gain insight into the molecular pathways that play a key role in this transition and propose a potential management strategy to overcome ADT resistance in select cancers. This represents a step forward towards personalized medicine guided by specific molecular markers of prostate cancer enabling more effective therapies targeted towards altered metabolic pathways.

PubMed Disclaimer

Comment on

References

    1. Karantanos T, Corn PG, Thompson TC.Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches Oncogenee-pub ahead of print 10 June 2013; doi:10.1038/onc.2013.206. - PMC - PubMed
    1. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45:747–55. - PMC - PubMed
    1. Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119:2405–12. - PMC - PubMed
    1. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013;45:739–46. - PMC - PubMed
    1. Lam YW. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol. 2013;2013:641089. - PMC - PubMed